Related Experiment Video
Updated: Jan 7, 2026
07:50
A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
16.4K
Clinical Manifestations
Hui Jue Janet Wang1,2, Myuri Ruthirakuhan1, Nathan Herrmann1,2,3
1Sunnybrook Research Institute, Toronto, ON, Canada.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 25, 2025
Summary
Nabilone effectively treats agitation in Alzheimer's disease (AD). Higher levels of inflammation, oxidative stress, and cholesterol metabolites predict a better response to nabilone for AD agitation.
Area of Science:
- Neuroscience
- Pharmacology
- Biomarker Discovery
Background:
- Agitation is a common and challenging neuropsychiatric symptom in Alzheimer's disease (AD).
- Previous research indicated nabilone's efficacy in improving agitation in AD patients over six weeks.
- Identifying predictive biomarkers for nabilone response is crucial for personalized treatment.
Purpose of the Study:
- To identify a combination of serum biomarkers that can predict treatment response to nabilone for agitation in Alzheimer's disease.
- To explore the relationship between specific biological markers and the efficacy of nabilone.
Main Methods:
- Agitation was measured using the Cohen-Mansfield Agitation Inventory (CMAI).
- Serum concentrations of 13 potential biomarkers were analyzed using linear regression.
- Multivariate models and bootstrapping were employed to identify significant predictors and estimate treatment effects.
Main Results:
- Four biomarkers (IL-6, ISO-8, 24S-OHC, clusterin) were associated with nabilone's efficacy.
- Higher levels of IL-6, ISO-8, and 24S-OHC, and lower clusterin predicted a greater reduction in agitation.
- Participants in the top quartile of predictive index scores showed significantly improved agitation with nabilone.
Conclusions:
- Elevated inflammation, oxidative stress, and specific cholesterol metabolites are linked to better nabilone response in AD agitation.
- A panel of biomarkers can potentially differentiate between responders and non-responders to nabilone treatment.
- This finding supports the development of a biomarker-guided approach for managing agitation in Alzheimer's disease.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
520
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
520
01:30Coronary Artery Disease III: Clinical Manifestations
299
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
299
01:25Endocarditis II: Clinical Features of Infective Endocarditis
364
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
364
01:26Heart Failure III: Clinical Manifestations
436
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
436
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
652
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
652
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
437
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
437